Virus-like particle vaccine with authentic quaternary epitopes protects against Zika virus-induced viremia and testicular damage
Journal of Virology · 2025
DOI: 10.1128/jvi.02322-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, 2025. Verfasst von Sandra R Abbo und 20 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Virology, Wageningen University & Research, Wageningen, the Netherlands. Hauptthemen laut MEDLINE: Zika Virus Infection, Zika Virus, Vaccines, Virus-Like Particle, Viremia. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Zika virus (ZIKV) caused unprecedented outbreaks in South America and the Caribbean in 2015–2016, leading primarily to a series of abnormalities in neonates termed congenital Zika syndrome. The threat of ZIKV reemergence has seen the development of multiple ZIKV vaccines that are at the preclinical stage or in early-stage clinical trials. Herein, we describe a pathway to the development of ZIKV vaccines generated using a baculovirus-insect cell expression system, which is widely applied for the manufacture of biologics for human use. Virus-like particle (VLP) vaccines comprising CprME and subviral particle (SVP) vaccines comprising prME were evaluated for their ability to mediate protection against ZIKV challenge in Ifnar1 −/− mice. Initial attempts resulted in VLP and SVP vaccines that failed to present quaternary epitopes and did not provide effective protection. To improve the SVP vaccine, two modifications were introduced: firstly, an alanine to cysteine substitution (A264C) in the E domain II region to promote the formation of stabilized E homodimers and, secondly, the use of Spodoptera frugiperda Sf9 insect cells that had been adapted to grow and produce vaccine at a neutral pH of 7. E homodimers largely retain their pre-fusion conformation at pH 7, which is a requirement for the induction of effective neutralizing antibody responses. The stabilized SVP-A26C vaccine induced high levels of neutralizing antibodies and protected male Ifnar1 −/− mice against viremia and testicular damage. Our study reiterates the need to present the immune system with E dimers arranged in authentic quaternary conformations and provides a scalable production method for this novel ZIKV vaccine. IMPORTANCE We describe the generation of a subviral particle (SVP) vaccine comprising prME proteins of ZIKV, with an envelope protein substitution, A264C, that stabilizes E dimer formation. The SVP vaccine was produced in a novel Sf9 insect cell line adapted to grow in suspension at pH 7. The study highlights the importance of challenge experiments to ascertain whether the responses induced by an experimental vaccine actually mediate protection against virus infection and disease. The study also reiterates the contention that effective flavivirus vaccines need to present the immunogen in an authentic tertiary and quaternary structure with a pre-fusion conformation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Virology, Wageningen University & Research, Wageningen, the Netherlands.
- Inflammation Biology Group, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
- Bioprocess Engineering, Wageningen University & Research, Wageningen, the Netherlands.
- Department of Virology I, National Institute of Infectious Diseases, Tokyo, Japan.
- Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- IBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
ORCID-Profile: Sandra R Abbo, Stefan W Metz, Andreas Suhrbier, Gorben P Pijlman
Zitieren
APA
Abbo, S. R., Yan, K., Geertsema, C., Hick, T. A. H., Altenburg, J. J., Nowee, G., van Toor, C., van Lent, J. W., Nakayama, E., Tang, B., Metz, S. W., Bhowmik, R., de Silva, A. M., Prow, N. A., Correia, R., Alves, P. M., Roldão, A., Martens, D. E., van Oers, M. M., …, & Pijlman, G. P. (2025). Virus-like particle vaccine with authentic quaternary epitopes protects against Zika virus-induced viremia and testicular damage. Journal of Virology. https://doi.org/10.1128/jvi.02322-24
Vancouver
Abbo SR, Yan K, Geertsema C, Hick TAH, Altenburg JJ, Nowee G, et al. Virus-like particle vaccine with authentic quaternary epitopes protects against Zika virus-induced viremia and testicular damage. Journal of Virology. 2025. doi:10.1128/jvi.02322-24
BibTeX
@article{Abbo2025,
author = {Abbo, Sandra R and Yan, Kexin and Geertsema, Corinne and Hick, Tessy A H and Altenburg, Jort J and Nowee, Gwen and van Toor, Chris and van Lent, Jan W and Nakayama, Eri and Tang, Bing and Metz, Stefan W and Bhowmik, Ryan and de Silva, Aravinda M and Prow, Natalie A and Correia, Ricardo and Alves, Paula M and Roldão, António and Martens, Dirk E and van Oers, Monique M and Suhrbier, Andreas and Pijlman, Gorben P},
title = {Virus-like particle vaccine with authentic quaternary epitopes protects against Zika virus-induced viremia and testicular damage},
journal = {Journal of Virology},
year = {2025},
doi = {10.1128/jvi.02322-24}
}
EUVIMED